Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors

⟵ Back to Search Results

Beigene Study ID

BGB-A317-fruquintinib-201

ClinicalTrials.gov ID

NCT04716634

China Drug Trials ID

CTR20211070

Sex: All

Age: 18 Years / N/A

No Study Documents

Sex: All

Age: 18 Years / N/A

No Study Documents